Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been given an average recommendation of “Hold” by the twelve brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $7.31.

MRVI has been the subject of a number of recent analyst reports. Robert W. Baird lowered Maravai LifeSciences from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $9.00 to $3.00 in a research report on Wednesday, February 26th. Bank of America decreased their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Stifel Nicolaus set a $5.00 target price on shares of Maravai LifeSciences in a report on Friday, March 21st. The Goldman Sachs Group lowered shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and decreased their target price for the company from $7.00 to $4.25 in a research note on Thursday, December 5th. Finally, Baird R W downgraded Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th.

Maravai LifeSciences Stock Performance

MRVI stock opened at $2.21 on Thursday. The stock has a market capitalization of $562.08 million, a PE ratio of -1.35 and a beta of -0.08. The stock’s 50 day simple moving average is $3.55 and its 200 day simple moving average is $5.45. Maravai LifeSciences has a 12-month low of $2.07 and a 12-month high of $11.56. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the transaction, the general counsel now owns 167,618 shares of the company’s stock, valued at $843,118.54. This trade represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.63% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alpha Wealth Funds LLC bought a new position in shares of Maravai LifeSciences in the fourth quarter worth approximately $386,000. Delta Investment Management LLC lifted its stake in shares of Maravai LifeSciences by 285.4% during the 4th quarter. Delta Investment Management LLC now owns 332,993 shares of the company’s stock valued at $1,815,000 after buying an additional 246,592 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Maravai LifeSciences by 22.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 251,214 shares of the company’s stock worth $1,369,000 after buying an additional 45,454 shares during the period. Systematic Financial Management LP increased its stake in Maravai LifeSciences by 2.3% in the 4th quarter. Systematic Financial Management LP now owns 1,649,544 shares of the company’s stock worth $8,990,000 after buying an additional 37,383 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Maravai LifeSciences in the 4th quarter worth $78,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.